Read all posts

High-Dose Omega-3s May Lower AD Risk in APOE4 Carriers

Giving long-term high doses of docosahexaenoic acid to carriers of the apolipoprotein E ε4 ( APOE4) allele before the onset of Alzheimer's disease (AD) dementia may reduce the risk for AD, or delay the onset of symptoms, and should be studied, according to an expert review.

Read the article on Medpagetoday

Dr. Sears Comments:

Dr. Barry Sears
Alzheimer’s is an inflammatory disease.  The only way to resolve inflammation is by increasing the resolution response that generated by resolvins that come from omega-3 fatty acids.  To get adequate levels in the brain, requires adequate levels in the blood.  The omega-3 fatty acids (both EPA and DHA) enter the brain via transport mechanism mediated by ApoE.  Those with ApoE4 mutant will simply  require more EPA and DHA in the blood to get enough into the brain to resolve the inflammation that causes Alzheimer’s.  I don’t consider the levels that they used to be high-dose, instead I would call just above placebo-dose

Leave a Reply

Your email address will not be published. Required fields are marked *